Hepatocellular Carcinoma Epidemiology Forecast 2025-2034

According to the National Health Institute, hepatocellular carcinoma is the fifth most common cause of cancer globally. In 2018, approximately 841,000 new cases of hepatocellular carcinoma were diagnosed. It is the most common type of primary liver cancer, often linked to chronic liver diseases like hepatitis B/C and cirrhosis. The hepatocellular carcinoma epidemiology forecast report will provide a comprehensive analysis of the disease's prevalence, incidence trends, and patient demographics across key regions.

Hepatocellular Carcinoma Epidemiology Forecast Report Coverage

The “Hepatocellular Carcinoma Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hepatocellular carcinoma. It projects the future incidence and prevalence rates of hepatocellular carcinoma cases across various populations. The study covers age, gender, and type as major determinants of the hepatocellular carcinoma population. The report highlights patterns in the prevalence of hepatocellular carcinoma over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on hepatocellular carcinoma epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hepatocellular Carcinoma Understanding: Disease Overview

Hepatocellular carcinoma is a primary liver cancer that develops from hepatocytes, is frequently linked to chronic liver illnesses such as cirrhosis, non-alcoholic fatty liver disease (NAFLD), and hepatitis B and C. The major risk of hepatocellular carcinoma includes aflatoxin exposure, heavy alcohol use, obesity, and persistent viral infections. Early-stage hepatocellular carcinoma frequently shows no symptoms, with weight loss, abdominal pain, and jaundice developing later. Alpha-fetoprotein (AFP) testing and imaging methods (MRI, CT scan) are used in the diagnosis process. Transarterial chemoembolization (TACE), liver transplantation, radiofrequency ablation, surgical resection, and, in more advanced cases, targeted medicines like sorafenib and immunotherapy are available as treatment options for hepatocellular carcinoma.

Hepatocellular Carcinoma Epidemiology Perspective

The hepatocellular carcinoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for hepatocellular carcinoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hepatocellular carcinoma and their trends. The hepatocellular carcinoma detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to an article published in the National Health Institute, the burden of liver cancer is increasing globally. The World Health Organization estimates that more than 1 million people will die from liver cancer by 2030.
• According to research studies, India has incidence of 2.15 per 100,000, prevalence 2.27 per 100,000, and mortality 2.21 per 100,000 rate of hepatocellular carcinoma.?
• According to an article published in JAMA, hepatocellular carcinoma accounts for 75% to 85% of primary liver cancers and for the majority of liver cancer diagnoses and deaths in the United States.

Country-wise Hepatocellular Carcinoma Epidemiology Segment

The hepatocellular carcinoma epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

?The epidemiology of hepatocellular carcinoma (HCC) shows significant variation across countries. In India, the current incidence (2.15 per 100,000), prevalence (2.27 per 100,000), and mortality (2.21 per 100,000) rates are relatively low compared to global averages. However, the annual rates of increase for these parameters are notably higher, indicating a rapidly growing burden. In contrast, East Asia and Africa bear the highest overall burden of HCC, largely due to widespread hepatitis B and C infections and limited access to healthcare resources. Meanwhile, in Western regions such as the United States and Europe, both the incidence and mortality rates of HCC are rising swiftly, driven by increasing cases of obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). This country-wise disparity highlights the need for region-specific strategies in HCC prevention and control.

Hepatocellular Carcinoma: Treatment Overview

Hepatocellular carcinoma treatment depends on tumor stage, liver function, and overall health. Early-stage hepatocellular carcinoma may be treated with surgical resection or liver transplantation, offering the best chance for cure. For localized but unresectable tumors, ablation techniques like radiofrequency ablation and microwave ablation are effective. Transarterial chemoembolization and transarterial radioembolization are used for intermediate-stage hepatocellular carcinoma. Advanced cases are managed with systemic therapies, including targeted drugs like sorafenib and lenvatinib, as well as immunotherapy agents such as atezolizumab and bevacizumab. Emerging treatments and combination therapies continue to improve outcomes for hepatocellular carcinoma patients.

Key Questions Answered

• What are the key findings of Hepatocellular Carcinoma epidemiology in the 8 major markets?
• What will be the total number of patients with hepatocellular carcinoma across the 8 major markets during the forecast period?
• What was the country-wise hepatocellular carcinoma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hepatocellular carcinoma patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of hepatocellular carcinoma during the forecast period of 2025-2034?
• What are the currently available treatments in the hepatocellular carcinoma market?
• What are the disease risks, signs, symptoms, and unmet needs of hepatocellular carcinoma?

Scope of the Hepatocellular Carcinoma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Hepatocellular Carcinoma based on several factors.
• Hepatocellular Carcinoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Hepatocellular Carcinoma report helps to identify the patient population and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.